Sitagliptin: The first dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

Formulary

Volumn 41, Issue 9, 2006, Pages 434-441

  Schlesselman, Lauren S ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; SITAGLIPTIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTHRALGIA; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFECT; DRUG FORMULARY; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN SYNTHESIS; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN DEGRADATION; REVIEW;

EID: 33749983928     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. International Diabetes Federation. Diabetes Atlas; Executive Summary. 2nd edition. Available at: http://www.catlas.idf.org/webdata/does/Atlas%202 003-Summary.pdf. Accessed August 21, 2006.
2. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005. Atlanta, GA: US. Department of Health and Human Services, Centers for Disease Control and Prevention, 2005. Available at: http://www. diabetes.org/uedocuments/NationalDiabetes FactSheetRev.pdf. Accessed August 21, 2006.
3. Centers for Disease Control and Prevention. NCHS-NHIS-Data from the January-September 2005 (Released 03/2006). Available at: http://www.cdc.gov/ nchs/about/majornhis/released200603.htm. Centers for Disease Control and Prevention website. Accessed August 21, 2006.
4. Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26:917-932.
5. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care. 1999;22:403-408.
6. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care. 2006;29(suppl 1):S4-S42.
7. Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharm Ther. 2005;78:675-688.
8. 14C]sitagliptin (MK-0431) in humans [abstract]. J Clin Pharmacol. 2005;45:1067-1096. Abstract 87.
9. Narita H, Nonaka K, Stevens C, Okuyama K, Fumimoto G, et al. Multiple dose administration of sitagliptin, a dipeptidyl peptide IV (DPP-IV) inhibitor, in healthy Japanese subjects [abstract]. Presented at: American Diabetes Association 66th Annual Scientific Sessions; June 6-13, 2006; Washington, DC. Abstract 533-P.
10. Scott RS, Hartley P, Luo E, et al. Use of sitagliptin in patients with type 2 diabetes (T2DM) and renal insufficiency (RI) [abstract]. Presented at: American Diabetes Association 66th Annual Scientific Sessions; June 6-13, 2006; Washington, DC. Abstract 1997-PO.
11. Stevens C, Bergman AJ, Liu Q, Luo W, Wang AQ, et al. Lack of clinically significant effect of moderate hepatic insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a dipeptidyl-peptidase-IV (DPP-IV) inhibitor [abstract]. Clin Pharm Ther. 2006;79;P49. Abstract PII-49.
12. Herman G, Zhao PL, Dietrich B, et al. The DP-IV inhibitor MK-0431 enhances active GLP-1 and reduces glucose following an OGTT in type 2 diabetics [abstract]. Diabetologia. 2004;47(suppl 1):A287.
13. Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006;28:55-72.
14. Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharm Ther. 2005;78:675-688.
15. Nonaka K, Kakikawa T, Sato A, et al. Twelve-week efficacy and tolerability of sitagliptin, a dipeptidyl peptidase-IV (DPP-4) inhibitor, in Japanese patients with T2DM [abstract]. Presented at: American Diabetes Association 66th Annual Scientific Sessions; June 9-13 2006: Washington, DC. Abstract 537-P.
16. Raz I, Hanefeld M, Xu L, Caria C. et al. Sitagliptin monotherapy improved glycemic control and beta-cell function after 18 weeks in patients with type 2 diabetes (T2DM) [abstract] Presented at: American Diabetes Association 66th Annual Scientific Sessions; June 9-13 2006: Washington, DC. Abstract 1996-PO.
17. Aschner P, Kipnes M, Lunceford J, Mickel C. Davies MJ, Williams-Herman D. Sitagliptin monotherapy improved glycemic control in the fasting and postprandial states and beta-cell function after 24 weeks in patients with type 2 diabetes (T2DM) [abstract]. Presented at: American Diabetes Association 66th Annual Scientific Sessions; June 9-13 2006; Washington, DC. Abstract 1995-PO.
18. Mu J, Zhou Y, Woods J, Li Z, et al. Direct comparison of efficacy and durability of DPP-4 inhibitor, PPARΓ agonist and sulfonylurea on glycemic control and B-cell function in a rodent model of type 2 diabetes. Presented at: American Diabetes Association 66th Annual Scientific Sessions; June 9-13 2006; Washington, DC. Abstract 588-P.
19. Brazg R, Thomas K, Zhao P, Xu L, Chen X, Stein P. Effect of adding MK-0431 to on-going metformin therapy in type 2 diabetic patients who have inadequate glycemic control on metformin [abstract]. Presented at: American Diabetes Association 65th Annual Scientific Sessions; June 10-14, 2005; San Diego, Calif. Abstract 11-OR.
20. Karasik A, Charbonnel B, Liu J, Wu M, Meehan A, Meininger G. Sitaglipitin added to ongoing metformin therapy enhanced glycemic control and beta-cell function in patients with type 2 diabetes. Presented at: American Diabetes Association 66th Annual Scientific Sessions; June 9-13, 2006; Washington, DC. Abstract 501-P.
21. Rosenstock J, Brazg R, Andryuk PJ, McCrary Sisk C, Lu K, Stein P. Addition of sitagliptin to pioglitazone improved glycemic control with neutral weight effect over 24 weeks in inadequately controlled type 2 diabetes (T2DM) [abstract]. Presented at: American Diabetes Association 66th Annual Scientific Sessions; June 9-13, 2006; Washington, DC. Abstract 556-P.
22. Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006;28:55-72.
23. Stevens C, Van Dyck K, Yi B, et al. Single doses of MK-0431, an inhibitor of dipeptidyl peptidase-IV, raise active GLP-1 levels without causing hypoglycemia in healthy subjects [abstract]. Presented at: American Diabetes Association 65th Annual Scientific Sessions; June 10-14, 2005; San Diego, Calif. Abstract 493-P.
24. Herman GA, Bergman A, Fang L, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of MK-0431 over 28 days in middle-aged, obese subjects [abstract]. Presented at: American Diabetes Association 65th Annual Scientific Sessions; June 10-14, 2005; San Diego, Calif. Abstract 497-P.
25. Scott R, Hartley P, Luo E, et al. Use of sitagliptin in patients with type 2 diabetes (T2DM) and renal insufficiency (RI) [abstract]. Presented at: American Diabetes Association 66th Annual Scientific Sessions; June 6-13, 2006; Washington, DC. Abstract 1997-PO.
26. Wright D, Maes A, Yi B, et al. Multiple dose administration of MK-0431 (sitagliptin), an inhibitor of dipeptidyl peptidase-IV does not meaningfully alter the plasma pharmacokinetics or pharmacodynamics of single doses of warfarin [abstract]. Clin Pharm Ther. 2006;79;P76. Abstract PIII-64.
27. Ruddy MK, Bergman AJ, Zheng W, et al. Sitagliptin, a DPP-IV inhibitor, does not inhibit the pharmacokinetics of sulfonylurea, glyburide [abstract]. Presented at: American Diabetes Association 66th Annual Scientific Sessions; June 9-13, 2006; Washington, DC. Abstract 558-P.
28. Herman G, Bergman A, Yi B, et al. Co-administration of MK-0431 and metformin in patients with type 2 diabetes does not alter the pharmacokinetics of MK-0431 or metformin [abstract]. Presented at: American Diabetes Association 65th Annual Scientific Sessions; June 10-14, 2005; San Diego, Calif. Abstract 2099-PO.
29. Mistry G, Bergman A, Luo W, et al. Effects of sitagliptin on the pharmacokinetics (PK) of rosiglitazone in healthy subjects [abstract]. Presented at: American Diabetes Association 66th Annual Scientific Sessions; June 6-13, 2006; Washington, DC. Abstract 2001-PO.
30. Krishna R, Bergman AJ, Larson P, et al. Effect of a single cyclosporine A (Neoral) dose on the single-dose pharmacokinetics (PK) of sitagliptin (MK-0431), a dipeptidyl peptidase-IV inhibitor (DPP-IV), in healthy male subjects [abstract]. Clin Pharm Ther. 2006;79;P63. Abstract PIII-17.
31. Bergman AJ, Cote J, Maes A, et al. Sitagliptin (MK-0431), a selective dipeptidyl-peptidase-IV (DPP-IV) inhibitor, does not affect the pharmacokinetics of simvastatin in humans [abstract]. Clin Pharm Ther. 2006;79;P48. Abstract PII-46.
32. Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006;28:55-72.